IAB22M2C

Drug Profile

IAB22M2C

Alternative Names: 89Zr Df IAB22M2C; IAB 22 M2C

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Graft-versus-host disease

Most Recent Events

  • 01 Apr 2017 Phase-I clinical trials in Cancer (Diagnosis, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03107663)
  • 01 Apr 2017 Phase-I clinical trials in Graft-versus-host disease (Diagnosis, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03107663)
  • 15 Sep 2016 Lonza and ImaginAb complete a development and clinical supply program for IAB22M2C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top